Internal and Emergency Medicine

, Volume 4, Issue 5, pp 367–373

Future drugs for migraine

  • Ivano Farinelli
  • Sergio De Filippis
  • Gabriella Coloprisco
  • Serena Missori
  • Paolo Martelletti
IM - Review

Abstract

Migraine is a complex, neurovascular disorder in which genetic and environmental factors interact. At present, frontline therapies in the acute treatment of migraine include the use of non-steroidal anti-inflammatory drugs and triptans. Evidence indicates that calcitonin gene-related peptide (CGRP) plays a fundamental role in the mechanism of migraine. CGRP is a strong vasodilatatory neuropeptide that is released from activated trigeminal sensory nerves. The development of CGRP antagonists has also been driven by the fact that triptans are vasoconstrictive and cannot be safely used in patients with cardiovascular risk factors. Olcegepant (BIBN4096) is the first CGRP antagonist for the treatment of migraine that has been tested in clinical trials, but because of its poor oral bioavailability, only the intravenous formulation has been tested. The first oral non-peptide CGRP antagonist, telcagepant, has been shown recently to be highly effective in the treatment of migraine attacks. This development can be considered as the most important pharmacological breakthrough for migraine treatment since the introduction of sumatriptan in the early 1990s. These results are also of importance, since they support an interesting pathophysiological hypothesis of migraine. The pipeline of future compounds for the treatment of acute migraine headaches include TPRV1 antagonists, prostaglandin E receptor 4 (EP4) receptor antagonists, serotonin 5HT1F receptor agonists and nitric oxide synthase inhibitors. The immediate future of a preventative treatment for migraine headaches is well represented by botulinum toxin type-A, glutamate NMDA receptor antagonists, gap-junction blocker tonabersat and an angiotensin type 1 blocker candesartan.

Keywords

Migraine Acute treatment CGRP antagonists Preventative therapy Neurotoxins Glutamate receptor antagonists 

References

  1. 1.
    Stovner LJ, Andrée C, on behalf of the Eurolight Steering Committee (2008) Impact of headache in Europe: a review for the Eurolight project. J Headache Pain 9:139–146PubMedCrossRefGoogle Scholar
  2. 2.
    Piane M, Lulli P, Farinelli I et al (2007) Genetics on migraine and pharmacogenomics: some considerations. J Headache Pain 8:334–339PubMedCrossRefGoogle Scholar
  3. 3.
    Di Piero V, Altieri M, Conserva G, Petolicchio B, Di Clemente L, Hietarachchi J (2007) “General practitioners’ co-operative” of the Casilino District of Rome. J Headache Pain 8:205–208PubMedCrossRefGoogle Scholar
  4. 4.
    Steiner TJ, Paemeleire K, Jensen R et al (2007) European principles of management of common headache disorders in primary care. J Headache Pain 8:S3–S47PubMedCrossRefGoogle Scholar
  5. 5.
    Tfelt-hansen P (2007) Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. J Headache Pain 8:127–134PubMedCrossRefGoogle Scholar
  6. 6.
    Martelletti P, Farinelli I, Colorisco G, Patacchioli FR (2007) Role of NSAIDs in acute treatment of headache. Drug Develop Res 68:276–281CrossRefGoogle Scholar
  7. 7.
    Ferraro D, Di Trapani G (2008) Topiramate in the prevention of paediatric migraine: literature review. J Headache Pain 9:147–150PubMedCrossRefGoogle Scholar
  8. 8.
    Valade D (2008) The emergency headache Center at the Lariboisière Hospital: 7 years with more than 70,000 patients. Intern Emerg Med 3:S3–S7PubMedCrossRefGoogle Scholar
  9. 9.
    Martellett P, Farinelli I, Steiner TJ, Working Group for Specialist Education, WHO’s Global Campaign to Reduce the Burden of Headache Worldwide (Lifting The Burden) (2008) Acute migraine in the emergency department: extending European principles of management. Intern Emerg Med 3:S17–S24CrossRefGoogle Scholar
  10. 10.
    Link AS, Kuris A, Edvinsson L (2008) Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9:5–12PubMedCrossRefGoogle Scholar
  11. 11.
    Lassen LH, Jacobsen VB, Haderslev PA et al (2008) Involvement of calcitonin gene-related peptide in migraine: regional blood flow and blood flow velocity in migraine patients. J Headache Pain 9:151–157PubMedCrossRefGoogle Scholar
  12. 12.
    Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta R, Ahmed T, Banerjee B, Bhatia M (2009) Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension-type headache subjects during inter-ictal period. J Headache Pain. doi:10.1007/s10194-009-0110-x
  14. 14.
    Edvinsson L, Alm R, Shaw D et al (2002) Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434:49–53PubMedCrossRefGoogle Scholar
  15. 15.
    Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedCrossRefGoogle Scholar
  16. 16.
    Salvatore CA, Hershey JC, Corcoran HA et al (2008) Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 324:416–421PubMedCrossRefGoogle Scholar
  17. 17.
    Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312PubMedCrossRefGoogle Scholar
  18. 18.
    Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123PubMedCrossRefGoogle Scholar
  19. 19.
    Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:3129–3136Google Scholar
  20. 20.
    Murata Y, Masuko S (2006) Peripheral and central distribution of TRPV1, substance P and CGRP of rat corneal neurons. Brain Res 1085:87–94PubMedCrossRefGoogle Scholar
  21. 21.
    Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181PubMedCrossRefGoogle Scholar
  22. 22.
    Szallasi A, Cruz F, Geppetti P (2006) TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 12:545–554PubMedCrossRefGoogle Scholar
  23. 23.
    Chizh BA, O’Donnell MB, Napolitano A et al (2007) The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132:132–141PubMedCrossRefGoogle Scholar
  24. 24.
    Nicoletti P, Trevisani M, Manconi M et al (2008) Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 28:9–17PubMedCrossRefGoogle Scholar
  25. 25.
    Farinelli I, Martelletti P (2007) Aspirin and tension-type headache. J Headache Pain 8:49–55PubMedCrossRefGoogle Scholar
  26. 26.
    Nakao K, Murase A, Ohshiro H et al (2007) CJ-023423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322:686–694PubMedCrossRefGoogle Scholar
  27. 27.
    Maubach KA, Davis RJ, Clark DE et al (2009) G BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 156:316–327PubMedCrossRefGoogle Scholar
  28. 28.
    Castro ME, Pascual J, Romón T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology 36:535–542PubMedCrossRefGoogle Scholar
  29. 29.
    Panconesi A (2008) Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 9:267–276PubMedCrossRefGoogle Scholar
  30. 30.
    Ayzenberg I, Oberman M, Leineweber K et al (2008) Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain 9:109–112PubMedCrossRefGoogle Scholar
  31. 31.
    Goldstein DJ, Roon KI, Offen WW et al (2001) Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358:1230–1234PubMedCrossRefGoogle Scholar
  32. 32.
    Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120:157–171PubMedCrossRefGoogle Scholar
  33. 33.
    Christiansen I, Iversen HK, Olesen J, Tfelt-hansen P (2008) Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. J Headache Pain 9:215–220PubMedCrossRefGoogle Scholar
  34. 34.
    Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J (1997) Nitric oxide synthase inhibition in migraine. Lancet 349:401–402PubMedCrossRefGoogle Scholar
  35. 35.
    Alderton WK, Angell AD, Craig C et al (2005) GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 145:301–312PubMedCrossRefGoogle Scholar
  36. 36.
    Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 213:504–508PubMedGoogle Scholar
  37. 37.
    Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135–138PubMedCrossRefGoogle Scholar
  38. 38.
    Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–43PubMedCrossRefGoogle Scholar
  39. 39.
    Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315–324PubMedCrossRefGoogle Scholar
  40. 40.
    Saper JR, Mathew NT, Loder EW, BoNTA-009 Study Group et al (2007) A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 8:478–485PubMedCrossRefGoogle Scholar
  41. 41.
    Evers S (2007) Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache. Neuropsychiatr Dis Treat 3:761–764PubMedGoogle Scholar
  42. 42.
    Cady R, Schreiber C (2008) Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 48:900–913PubMedCrossRefGoogle Scholar
  43. 43.
    Relja M, Poole AC, Schoenen J et al (2007) A multi-centre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27:492–503PubMedCrossRefGoogle Scholar
  44. 44.
    Ma QP (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 12:1589–1591PubMedCrossRefGoogle Scholar
  45. 45.
    Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH (2004) Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 24:735–739PubMedCrossRefGoogle Scholar
  46. 46.
    Sang CN, Ramadan NM, Wallihan RG et al (2004) LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well tolerated in acute migraine. Cephalalgia 24:596–602PubMedCrossRefGoogle Scholar
  47. 47.
    Weiss B, Alt A, Ogden AM et al (2006) Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 318:772–781PubMedCrossRefGoogle Scholar
  48. 48.
    Damodaram S, Thalakoti S, Freeman SE, Garrett FG, Durham PL (2009) Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49:5–20PubMedCrossRefGoogle Scholar
  49. 49.
    MaassenVanDenBrink A, van den Broek RW, de Vries R, Upton N, Parsons AA, Saxena PR (2000) The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20:538–545PubMedCrossRefGoogle Scholar
  50. 50.
    Tvedskov JF, Iversen HK, Olesen J (2004) A double-blind study of SB-220453 (tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 24:875–882PubMedCrossRefGoogle Scholar
  51. 51.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. doi: 10.1111/j.1468-2982.2008.01804.x
  52. 52.
    Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289:65–69PubMedCrossRefGoogle Scholar
  53. 53.
    Diener HC, Sacco RL, Yusuf S et al (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the prevention regimen for effectively avoiding second strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7:875–884PubMedCrossRefGoogle Scholar
  54. 54.
    Allena M, Katsarava Z, Nappi G, The COMOESTAS Consortium (2009) From drug-induced headache to medication overuse headache: a short epidemiological review, with a focus on Latin–American countries. J Headache Pain 10:71–76PubMedCrossRefGoogle Scholar
  55. 55.
    Ferrari A, Spaccapelo L, Gallesi D, Sternieri E (2009) Focus on headache as an adverse reaction to drugs. J Headache Pain. doi:10.1007/s10194-009-0127-1

Copyright information

© SIMI 2009

Authors and Affiliations

  • Ivano Farinelli
    • 1
  • Sergio De Filippis
    • 1
  • Gabriella Coloprisco
    • 1
  • Serena Missori
    • 1
  • Paolo Martelletti
    • 1
  1. 1.Department of Medical and Molecular Sciences, Regional Referral Headache Centre, II School of MedicineSapienza University of Rome, Sant’Andrea HospitalRomeItaly

Personalised recommendations